Singapore-based medtech startup Aevice Health has raised US$7 million in a Seed Plus funding round led by Coronet Ventures, with participation from existing and new investors. The funding aims to accelerate the company’s mission of making respiratory care more accessible and effective around the world, particularly for patients managing chronic respiratory conditions like asthma and COPD.

Founded in 2016, Aevice Health specializes in wearable respiratory monitoring solutions. Its flagship device, the AeviceMD, is a non-invasive, chest-worn sensor that continuously monitors key respiratory biomarkers such as wheezing, respiratory rate, and heart rate. The device is paired with an AI-powered platform that enables early detection of respiratory distress and facilitates remote patient monitoring by healthcare professionals.

The company’s technology is designed to help patients manage chronic respiratory diseases from the comfort of their homes while providing physicians with real-time data to make timely clinical decisions. The approach not only reduces unnecessary hospital visits but also helps to prevent acute exacerbations that can be costly and life-threatening if not caught early.

“Our vision is to shift respiratory care from the hospital to the home,” said Adrian Ang, co-founder and CEO of Aevice Health. “With this new funding, we’re looking to bring our solution to more markets and make a real difference for the millions of people who suffer from chronic respiratory conditions globally.”

Leading investor Coronet Ventures, a global VC firm with a focus on healthcare and technology, expressed strong confidence in Aevice Health’s impact-driven approach and its potential to transform the way respiratory care is delivered.

“Respiratory illnesses are among the most prevalent and costly chronic diseases worldwide,” said a spokesperson from Coronet Ventures. “Aevice Health’s platform stands out not only for its innovation, but also for its potential to scale globally and create tangible improvements in patient outcomes.”

The Seed Plus round also included follow-on investments from existing backers such as Seeds Capital, the investment arm of Enterprise Singapore, and Entrepreneur First, alongside new strategic investors from the Asia-Pacific and Middle East regions. These strategic partners are expected to help Aevice Health navigate regulatory pathways and distribution channels in international markets.

With the new capital, Aevice Health plans to expand its operations into key global markets including Japan, the United States, and the Middle East, where respiratory diseases are a leading cause of morbidity. The company will also invest in further clinical validation studies, product development, and team expansion to support its growth.

AeviceMD is currently undergoing clinical pilots in several hospitals across Singapore and Japan. Early results have shown promise in reducing hospital admissions and improving early intervention for patients with chronic respiratory issues.

The global burden of respiratory diseases continues to grow, exacerbated by aging populations, pollution, and the lingering effects of respiratory infections, including COVID-19. According to the World Health Organization, chronic respiratory diseases affect over 300 million people globally. With healthcare systems increasingly stretched, especially in low- and middle-income countries, scalable, tech-driven solutions like Aevice Health’s offer a lifeline.

In a market crowded with fitness wearables and consumer-grade monitors, Aevice Health has carved a niche in clinically validated, physician-led respiratory care. Its focus on long-term disease management and remote patient monitoring puts it in line with global trends toward preventative, home-based healthcare.

“We’re proud to be at the intersection of medical science and technology,” said Ang. “This funding round strengthens our ability to bring cutting-edge, affordable respiratory monitoring to the people who need it most.”

As the company moves into its next phase of growth, Aevice Health is positioning itself as a key player in the future of digital health, especially in respiratory care—a field that is increasingly critical as healthcare moves beyond hospitals and into the home.